C5 Personalised anticancer strategy: From innovation to impact
Tuesday 30 August 2016
09:00-12:00
Hilton Buenos Aires : Pacifico A, 3 hours
Organised by the FIP Special Interest Groups on Translational Research and Individualized Medicines, Pharmacokinetics and Pharmacodynamics and the FIP Hospital Pharmacy Section
Simultaneous translation in Spanish
Introduction
There are more than 200 different types of cancer. One in three people in developed countries will get cancer in their lifetime. Recent advances in medical genetics and human genetics have enabled a more detailed understanding of the impact of genetics in drug discovery and development. Pharmacists need to provide the best pharmaceutical care possible to individual patients by understanding current evidence and information. Pharmacists could enhance the effect of chemotherapy and quality of life by expanding their role in genomics and other -omics.
Learning objectives
At the conclusion of this knowledge-based session, participants will be able to:
- Explain the important of implementing personalised anticancer strategy based on pharmacogenomics
- Describe the other “-omics” technologies in drug discovery and development
- Describe current pharmaceutical practice in cancer chemotherapy
- Identify the role of pharmacists as genomics counsellors in the development of novel personalised anticancer strategies.
Chair
Ross McKinnon (Flinders Centre for Innovation in Cancer, Australia)
Programme
09:00
1) Pharmacogenomics: Genomics and drug response
Sam Harirforoosh (East Tennessee State University, USA)
09:40
2) Other “-omics” technologies in drug discovery and development
Aridaman Pandit (University Medical Center Utrecht, Netherlands)
10:20 – 10:40 Coffee/tea break
10:40
3) Pharmaceutical practice in cancer chemotherapy
Ross McKinnon (Flinders Centre for Innovation in Cancer, Australia)
11:20
4) Expanding the role of pharmacists as genomics counsellors
Jane Pruemer (University of Cincinnati, USA)
